Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

November 30, 2018

Study Completion Date

November 30, 2018

Conditions
Medullary Thyroid Carcinoma
Interventions
DRUG

111In-CP04

Radiopharmaceutical preparation

DRUG

111In-CP04 with co-administration of gelofusine/gelaspan

Radiopharmaceutical preparation with co-administration of gelofusine/gelaspan

Trial Locations (5)

Unknown

Department of Nuclear Medicine, Innsbruck Medical University, Innsbruck

Department of Nuclear Medicine, University Hospital Freiburg, Freiburg im Breisgau

Erasmus University Rotterdam, Rotterdam

Department of Endocrinology, Jagiellonian University Medical College, Krakow

Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Jagiellonian University

OTHER

collaborator

University Hospital Freiburg

OTHER

collaborator

Medical University Innsbruck

OTHER

collaborator

University Medical Centre Ljubljana

OTHER

collaborator

NATIONAL CENTRE FOR NUCLEAR RESEARCH, Poland

UNKNOWN

collaborator

Erasmus Medical Center

OTHER

collaborator

INRASTES, NCSR Demokritos, Athens, Greece

UNKNOWN

lead

Paola Anna Erba

OTHER

NCT03246659 - Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC | Biotech Hunter | Biotech Hunter